Recent pharmacodynamic and pharmacokinetic findings on oxaprozin

Inflammopharmacology

Volumn 10, Issue 3, 2002, Pages 185-239

  Rainsford, K D ^a   Omar, H ^a   Ashraf, A ^a   Hewson, A T ^a   Bunning, R A D ^a   Rishiraj, R ^a   Shepherd, P ^a   Seabrook, R W ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Albumin; Arthritis; Cytokines; NSAIDs; Propionic acids; Serotonin

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ATENOLOL; CAPTOPRIL; CLONIDINE; CROMOGLYCATE DISODIUM; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIAZEPAM; DICLOFENAC; DIPHENHYDRAMINE; FUROSEMIDE; IBUPROFEN; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KETOTIFEN; NIMESULIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PREDNISOLONE; PROTEOGLYCAN; SALBUTAMOL; SALICYLIC ACID; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; WARFARIN;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL TISSUE; ARTHRITIS; BINDING COMPETITION; CARTILAGE DEGENERATION; CATTLE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG UPTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; JOINT DESTRUCTION; LIGAND BINDING; MONONUCLEAR CELL; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SWINE; SYNOVIUM;

EID: 0036957293     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856002321168204     Document Type: Conference Paper

References (101)

1. Audet, P. R., Knowles, J. A., Troy, S. M., et al. (1988). Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics, Clin. Pharmacol. Ther. 44, 303-309.
2. Ashcroft, G. W., Crawford, T. B., Cundall, R. L., et al. (1973). 5-Hydroxytryptamine metabolism in affective illness: the effect of tryptophan administration, Psychol. Med. 3, 326-332.
3. Aubry, A. F., Markoglou, N., Adams, M. H., et al. (1995). The effect of co-administered drugs on oxaprozin binding to human serum albumin, J. Pharm. Pharmacol. 47, 937-944.
4. Aylward, M. and Maddock, J. (1973). Total and free-plasma tryptophan concentrations in rheumatoid disease, J. Pharm. Pharmacol. 25, 570-572.
5. Badawy, A. A.-B. (1982). Mechanisms of elevation of rat brain tryptophan concentration by various doses of salicylate, Br. J. Pharmacol. 76, 211-213.
6. Barracchini, A., Franceschini, N., Amicosante, G., et al. (1998). Can non-steroidal anti-inflammatory drugs act as metalloproteinase modulators? An in vitro study of inhibition of collagenase activity, J. Pharm. Pharmacol. 50, 1417-1423.
7. Barracchini, A., Minisola, G., Amicosante, G., et al. (2001). Oxaprozin: An NSAID able to inhibit the matrix metallo-proteinase activity, Inflammopharmacology 9, 143-146.
8. Barbato, F., Caliendo, G., La Rotonda, M. I., et al. (1986). Distribution coefficients by curve fitting: application to ionogenic nonsteroidal anti-inflammatory drugs, Quant. Struct.-Activity Relat. 5, 88-95.
9. Bender, D. A and McCreanor, G. M. (1982). The preferred route of kynurenine metabolism in the rat, Biochim. Biophys. Acta 717, 56-60.
10. Bickel, M. H. and Gerny, R. (1980). Drug distribution as a function of binding competition. Experiments with the distribution dialysis technique, J. Pharm. Pharmacol. 32, 669-674.
11. Bonney, S. L., Hedrich, D. A. and Walker, B. R. (1987). Oxaprozin, in: Nonsteriodal Anti-inflammatory Drugs. Mechanisms and Clinical Use, Lewis, A. J. and Furst, D. E. (Eds), pp. 473-486. Marcel Dekker, New York.
12. Bonney, S. L., Northington, R. S., Hedrich, D. A., et al. (1986). Renal safety of two analgesics used over the counter: ibuprofen and aspirin, Clin. Pharmacol. Ther. 40, 373-377.
13. Chiang, S. T., Morrison, G., Knowles, J. A., et al. (1982). Oxaprozin disposition in renal disease, Clin. Pharmacol. Ther. 31, 509-515.
14. Couchman, K. G. and Sheppeard, H. (1986). The effect of anti-rheumatic drugs on factors from porcine synovium inducing chondrocyte mediated cartilage degradation, Agents Actions 19, 116-122.
15. Crofford, L.J. (1997). COX-1 and -2 tissue expression; implications and prediction, J. Rheumatol. 24, 15-19.
16. Crofford, L. J., Wilder, R. L., Risimaki, A. P., et al. (1994). Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1β, phorbol ester, and corticosteroids, J. Clin. Invest. 93, 1095-1101.
17. Curzon, G. and Knott, P. J. (1973). Drugs influencing plasma and brain tryptophan, Br. J. Pharmacol. 48, 352P-353P.
18. Curzon, G., Friedel, J. and Knott, P. J. (1973). The effect of fatty acids on the binding of tryptophan to plasma protein, Nature 242, 198-200.
19. Davies, N. M. (1998). Clinical pharmacokinetics of oxaprozin, Clin. Pharmacokinet. 35, 425-436.
20. Davis, R. H., Fisher, J. S. and McGowan, L. (1968). Local antiphlogistic activity of L-phenylalanine and L-tryptophane, J. Endocrinol. 41, 603-604.
21. Dickens, B. F., Wegiicki, W. B., Li, Y. S., et al. (1992). Magnesium deficiency in vitro enhances free radical-induced intracellular oxidation and cytotoxicity in endothelial cells, FEBS Lett. 311, 187-191.
22. Dingle, J. T. (1983). Effect of NSAIDs on the production of catabolin by porcine synovium, Adv. Inflamm. Res. 10, 105-110.
23. Dixon, J. S. and Page, M. C. (1991). Interactions between non-steroidal anti-inflammatory drugs and H2-receptor antagonists or prostaglandin analogues, Rheumatol. Int. 11, 13-18.
24. Farndale, R. W., Buttle, D. J. and Barrett, A. J. (1986). Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue, Biochim. Biophys. Acta 883, 173-177.
25. Fernstrom, J. D. and Wurtman, R. J. (1972). Brain serotonin content: physiological regulation by plasma neutral amino acids, Science 178, 414-416.
26. Fitos, I. and Simonyi, M. (1986). Investigation on the binding of tryptophan enantiomers to human serum albumin, Acta Biochim. Biophys. 21, 237-245.
27. Francesconi, R. P. and Mager, M. (1975). Salicylate, tryptophan, and tyrosine hypothermia, Am. J. Physiol. 228, 1431-1435.
28. Fraser, A. D. and Howell, P. (1998). Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine, J. Anal. Toxicol. 22, 50-54.
29. Freeland, G. R., Northington, R. S., Hedrich, D. A., et al. (1988). Hepatic safety of two analgesics used over the counter: ibuprofen and aspirin, Clin. Pharmacol. Ther. 43, 473-479.
30. Friedman, P. A., Kappelman, A. H. and Kaufman, S. (1972). Partial purification and characterization of tryptophan hydroxylase from rabbit hindbrain, J. Biol. Chem. 247, 4165-4173.
31. Gal, E. M. (1975). Hydroxylation of tryptophan and its control in brain, Pavlov J. Biol. Sci. 10, 145-160.
32. Greenblatt, D. J., Matlis, R., Scavone, J. M., et al. (1985). Oxaprozin pharmacokinetics in the elderly, Br. J. Clin. Pharmacol. 19, 373-378.
33. Griffin, J. P. and D'Arcy, P. F. (1997). A Manual of Adverse Drug Reactions. Elsevier, Amsterdam.
34. Guerinot, F., Poitou, P. and Bohuon, C. (1974). Serotonin synthesis in the rat brain after acetylsalicylic acid administration, J. Neurochem. 22, 191-192.
35. Heyliger, S. O., Goodman, C. B., Ngong, J. M., et al. (1998). The analgesic effects of tryptophan and its metabolites in the rat, Pharmacol. Res. 38, 243-250.
36. Igari, T. and Shimamura, T. (1979). Serotonin metabolism and its enzymic activities in joint diseases, Clin. Orthoped. 139, 232-249.
37. Igari, T., Obara, K., Ono, S., et al. (1979). Tryptophan metabolism in the joint diseases, Acta Vitaminol. Enzymol. 29, 194-197.
38. Iwata, H., Okamoto, H. and Ko, S. (1975). Effects of various drugs on serum free and total tryptophan levels and brain tryptophan metabolism in rats, Jpn. J. Pharmacol. 25, 303-310.
39. Janssen, F. W., Jusko, W. J., Chiang, S. T., et al. (1980). Metabolism and kinetics of oxaprozin in normal subjects, Clin. Pharmacol. Ther. 27, 352-362.
40. Karim, A. (1996). Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications, J. Clin. Pharmacol. 36, 985-997.
41. Karim, A., Noveck, R., McMahon, F. G., et al. (1997). Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics, J. Clin. Pharmacol. 37, 267-278.
42. Kawai, S., Nishida, S., Kato, M., et al. (1998). Comparison of cyclooxygenase-1 and -2 inhibitory activities of various non-steroidal anti-inflammatory drugs using human platelets and synovial cells. Eur. J. Pharmacol. 347, 87-94.
43. Kelly, S. J. and Franklin, K. B. (1985). An increase in tryptophan in brain may be a general mechanism for the effect of stress on sensitivity to pain. Neuropharmacology 24, 1019-1025.
44. Kema, I. P., de Vries, E. G. and Muskiet, F. A. (2000). Clinical chemistry of serotonin and metabolites, J. Chromatogr. B: Biomed. Sci. Appl. 747, 33-48.
45. Kethu, S. R., Rukkannagari, S. and Lansford, C. L. (1999). Oxaprozin-induced symptomatic hepatotoxicity, Ann. Pharmacother. 33, 942-944.
46. Khan, S. B. and Hubsher, J. A. (1983). Effects of oxaprozin alone or in combination with aspirin on hemostasis and plasma protein binding, J. Clin. Pharmacol. 23, 139-146.
47. Knott, P. J. and Curzon, G. (1972). Free tryptophan in plasma and brain tryptophan metabolism, Nature 239, 452-453.
48. Kurowski, M. and Thabe, H. (1989). The transsynovial distribution of oxaprozin, Agents Actions 27, 458-460.
49. Lagrange, F., Penhourcq, F., Matoga, M., et al. (2000). Binding of ketoprofen enantiomers in various human albumin preparations, J. Pharm. Biomed. Anal. 23, 793-802.
50. Lanza, F. L. (1993). Gastrointestinal toxicity of newer NSAIDs, Am. J. Gastroenterol. 88, 1318-1323.
51. Lanza, F. L., Hubsher, J. A. and Walker, B. R. (1981). Gastroscopic evaluation of the effect of aspirin and oxaprozin on the gastric mucosa, J. Clin. Pharmacol. 21, 157-161.
52. Lewis, A. J., Janssen, F. W., Bonney, S. L., et al. (1985). Oxaprozin, in: Anti-Inflammatory and Anti-Rheumatic Drugs, Vol. II: Newer Anti-Inflammatory Drugs, Rainsford, K. D. (Ed.), pp. 189-208. CRC Press, Boca Raton, FL.
53. Lucker, P. W., Venitz, J., Ahrens, S., et al. (1987). Gastric irritation of oxaprozin, a new nonsteroidal, antiinflammatory drug, in comparison to acetylsalicyic acid and indomethacin: a gastric potential difference analysis, Methods Find. Exp. Clin. Pharmacol. 9, 469-475.
54. Lussier, A., Lebel, E. and Tetreault, L. (1982). Gastrointestinal blood loss of oxaprozin and aspirin with placebo control, J. Clin. Pharmacol. 22, 173-178.
55. Manoukian, A. V. and Carson, J. L. (1996). Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention, Drug Safety 15, 64-71.
56. McArthur, J. N. (1979). The pharmacological consequences of the binding of anti-rheumatic drugs to plasma proteins in the treatment of rheumatoid arthritis, Agents Actions 9, 212-216.
57. McArthur, J. N. and Dawkins, P. D. (1969). The effect of sodium salicylate on the binding of L-tryptophan to serum proteins, J. Pharm. Pharmacol. 21, 744-750.
58. McArthur, J. N. and Smith, M. J. (1972). Action of salicylates, N. Engl. J. Med. 287, 361.
59. McArthur, J. N., Smith, M. J. and Hamilton, E. B. (1971a). Protein-bound peptides in human serum, Br. Med. J. 4, 230.
60. McArthur, J. N., Dawkins, P. D., Smith, M. J., et al. (1971b). Mode of action of antirheumatic drugs, Br. Med. J. 2, 677-679.
61. McArthur, J. N., Smith, M. J. and Freeman, P. C. (1972). Anti-inflammatory substance in human serum, J. Pharm. Pharmacol. 24, 669- 671.
62. McMenamy, R. H. and Oncley, J. L. (1958). The specific binding of L-tryptophan to serum albumin, J. Biol. Chem. 233, 1436-1447.
63. Miller, L. G. (1992). Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug, Clin. Pharm. 11, 591-603.
64. Mitnick, P. D., Greenberg, A., Deoreo, P.B., et al. (1980). Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney, Clin. Pharmacol. Ther. 28, 680-689.
65. Monaghan, J. M., Cook, K., Gara, D., et al. (1997). Determination of nitrite and nitrate in human serum, J. Chromatogr. A 770, 143-149.
66. Oldendorf, W. H. (1971). Uptake of radiolabelled essential amino acids by brain following arterial injection, Proc. Soc. Exp. Biol. Med. 136, 385-386.
67. Ochs, H. R., Greenblatt, D. J. and Knuchel, M. (1986). Oxaprozin pharmacokinetics in patients with congestive heart failure, Arzneimittelforschung 36, 1837-1840.
68. Pardridge, W. M. (1977). Regulation of amino acid availability in the brain, in: Nutrition and the Brain, R. J. Wurtman and J. J. Wurtman (Eds), pp. 141-204. Raven Press, New York, NY.
69. Pulini, M. (1995). False-positive benzodiazepine urine test due to oxaprozin, J. Am. Med. Ass. 273, 1905-1906.
70. Purdum III, P. P., Sheldon, S. L., Boyd, J. W., et al. (1994). Oxaprozin-induced fulminant hepatitis, Ann. Pharmacother. 28, 1159-1161.
71. Rainsford, K. D. (1985). Preliminary investigations on the pharmacological control of catabolin-induced cartilage destruction in vitro, Agents Actions 16, 55-57.
72. Rainsford, K. D. (1988). Comparative irritancy of oxaprozin on the gastrointestinal tract of rats and mice: relationship to drug uptake and effects in vivo on eicosanoid metabolism, Aliment Pharmacol. Ther. 2, 439-450.
73. Rainsford, K. D., Brune, K. and Whitehouse, M. W. (Eds) (1981). Trace Elements in the Pathogenesis and Treatment of Inflammation. Birkhäuser Verlag, Basel, Boston, Stuttgart.
74. Rainsford, K. D., Davies, A., Mundy, L., et al. (1989). Comparative effects of azapropazone on cellular events at inflamed sites. Influence on joint pathology in arthritic rats, leucocyte superoxide and eicosanoid production, platelet aggregation, synthesis of cartilage proteoglycans, synovial production and actions of interleukin-1 in cartilage resorption correlated with drug uptake into cartilage in vitro, J. Pharm. Pharmacol. 41, 322-330.
75. 2 production and production of interleukins 1, 6 and 8, in human and porcine explants in organ culture, J. Pharm. Pharmacol. 48, 991-998.
76. Rainsford, K. D., Ginsburg, I. and Gadd, S. J. (1997). A comparison between the effects of meloxicam and other NSAIDs on the production of oxyradicals by human polymorphonuclear leucocytes, Immunopharmacology 5, 9-19.
77. Rainsford, K. D., Milanino, R., Sorenson, J. R. J., et al. (Eds) (1998), Copper and Zinc in Inflammatory and Degenerative Diseases. Kluwer Academic Publishers, Dordrecht, Boston, London.
78. Rainsford, K. D., Skerry, T. M., Chindemi, P., et al. (1999). Effects of the NSAIDs, meloxicam and indomethacin, on cartilage proteoglycan synthesis and joint responses to calcium pyrophosphate crystals in dogs, Vet. Res. Commun. 23, 101-113.
79. Rothstein, R. (1998). Safety profiles of leading nonsteroidal anti-inflammatory drugs, Am. J. Med. 105, 39S-43S.
80. Ruelius, H. W., Kirkman, S. K., Young, E. M., et al. (1986). Reactions of oxaprozin-1-0-acyl glucuronide in solutions of human plasma and albumin, Adv. Exp. Med. Biol. 197, 431-441.
81. Ruelius, H. W. (1987). Extrapolation from animals to man: predictions, pitfalls and perspectives, Xenobiotica 17, 255-265.
82. Saklatvala, J., Pilsworth, L. M., Sarsfield, S. J., et al. (1984). Pig catabolin is a form of interleukin 1. Cartilage and bone resorb, fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein, Biochem. J. 224, 461-466.
83. Sandyk, R. (1992). L-Tryptophan in neuropsychiatric disorders: a review, Int. J. Neurosci. 67, 127-144.
84. Scavone, J. M., Greenblatt, D. J., Matlis, R., et al. (1986). Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine, Eur. J. Clin. Pharmacol. 31, 371-374.
85. Scavone, J. M., Ochs, H. R., Greenblatt, D. J., et al. (1988). Pharmacokinetics of oxaprozin in women receiving conjugated estrogen, Eur. J. Clin. Pharmacol. 35, 105-108.
86. Shriver, D. A., Dove, P. A., White, C. B., et al. (1977). A profile of the gastrointestinal toxicity of aspirin, indomethacin, oxaprozin, phenylbutazone, and fentiazac in arthritic and Lewis normal rats, Toxicol. Appl. Pharmacol. 42, 75-83.
87. Siegle, I., Klein, T., Backman, J. T., et al. (1998). Expression of cyclooxygenase-1 and cyclooxygenase-2 in human synovial tissue. Differential evaluation of cyclooxygenase-2 in inflammatory joint diseases, Arth. Rheum. 41, 122-129.
88. Simon, L. S., Zhao, S. Z., Arguelles, L. M., et al. (1998). Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis, Clin. Ther. 20, 1218-1235.
89. Smith, H. G. and Lakatos, C. (1971). Effects of acetylsalicylic acid on serum protein binding and metabolism of tryptophan in man, J. Pharm. Pharmacol. 23, 180-189.
90. Spano, P. F., Tagliamonte, A., Tagliamonte, P., et al. (1971). Stimulation of brain dopamine synthesis by gamma-hydroxybutyrate, J. Neurochem. 18, 1831-1836.
91. Suwa, T., Urano, H., Kohno, Y., et al. (1987). Comparative studies on the gastrointestinal lesions caused by several nonsteroidal anti-inflammatory agents in rats, Agents Actions 21, 167-172.
92. Tagliamonte, A., Tagliamonte, P., Perez-Cruet, J., et al. (1971a). Increase of brain tryptophan caused by drugs which stimulate serotonin synthesis, Nature New. Biol. 229, 125-126.
93. Tagliamonte, A., Tagliamonte, P., Perez-Cruet, J., et al. (1971b). Effect of psychotropic drugs on tryptophan concentration in the rat brain, J. Pharmacol. Exp. Ther. 177, 475-480.
94. Tagliamonte, A., Biggio, G., Vargiu, L., et al. (1973a). Free tryptophan in serum controls brain tryptophan level and serotonin synthesis. Life Sci. II, 12, 277-287.
95. Tagliamonte, A., Biggio, G., Vargiu, L., et al. (1973b). Increase of brain tryptophan and stimulation of serotonin synthesis by salicylate. J. Neurochem. 20, 909-912.
96. Todd, P. A. and Brogden, R. N. (1986). Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, Drugs 32, 291-312.
97. Weaver, A., Rubin, B., Caldwell, J., et al., (1995). Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee, Clin. Ther. 17, 735-745.
98. Weil-Fugazza, J., Godefroy, F. and Besson, J. M. (1979). Changes in brain and spinal tryptophan and 5-hydroxyindoleacetic acid levels following acute morphine administration in normal and arthritic rats, Brain Res. 175, 291-301.
99. Weil-Fugazza, J., Godefroy, F., Coudert, D., et al. (1980). Total and free serum tryptophan levels and brain 5-hydroxytryptamine metabolism in arthritic rats, Pain 9, 319-325.
100. Wells, D. S., Janssen, F. W. and Ruelius, H. W. (1987). Interactions between oxaprozin glucuronide and human serum albumin, Xenobiotica 17, 1437-1449.
101. Wong, C.-L., Wai, M.-K. and Roberts, M. B. (1980). The effect of aspirin and paracetamol on the increased naloxone potency induced by morphine pre-treatment, Eur. J. Pharmacol. 67, 241-246.